TY - JOUR
T1 - Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families
AU - GenoMEL Study Group
AU - Tucker, Margaret A.
AU - Avril, Marie Françoise
AU - Azizi, Esther
AU - Bergman, Wilma
AU - Bishop, D. Timothy
AU - Bressac-de Paillerets, Brigitte
AU - Bruno, William
AU - Calista, Donato
AU - Cannon-Albright, Lisa A.
AU - Cuellar, Francisco
AU - Cust, Anne E.
AU - Demenais, Florence
AU - Elder, David E.
AU - Gerdes, Anne Marie
AU - Ghiorzo, Paola
AU - Grazziotin, Thais C.
AU - Hansson, Johan
AU - Harland, Mark
AU - Hayward, Nicholas K.
AU - Hocevar, Marko
AU - Höiom, Veronica
AU - Ingvar, Christian
AU - Landi, Maria Teresa
AU - Landman, Gilles
AU - Larre-Borges, Alejandra
AU - Leachman, Sancy A.
AU - Mann, Graham J.
AU - Nagore, Eduardo
AU - Olsson, Håkan
AU - Palmer, Jane M.
AU - Perić, Barbara
AU - Pritchard, Antonia
AU - Puig, Susana
AU - van der Stoep, Nienke
AU - Wadt, Karin A.W.
AU - Whitaker, Linda
AU - Yang, Xiaohong R.
AU - Newton Bishop, Julia A.
AU - Gruis, Nelleke A.
AU - Kanetsky, Peter A.
A2 - Taylor, Nicholas J.
A2 - Mitra, Nandita
A2 - Goldstein, Alisa M.
A2 - Pjanova, Dace
N1 - Funding Information:
This work was supported by the European Commission under the 6th and 7th Framework Programme [LSH-CT-2006-018702]; Cancer Research UK Programme Awards (C588/A4994 and C588/ A10589); a Cancer Research UK Project Grant (C8216/A6129); the US National Institutes of Health (R01-CA83115, R01CA5558-01A2 [MTL], 5R25-CA147832-04 [NJT]); the intramural Research Program of the NIH, National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics; the National Health and Medical Research Council of Australia (NHMRC 107359, 402761, 633004, 566946, 211172); the Cancer Council New South Wales (project grant 77/00, 06/10); the Cancer Institute New South Wales (CINSW 05/TPG/1-01, 10/TPG/1-02); the Cancer Council Victoria and the Cancer Council Queensland (project grant 371); CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior); FAPESP (Fundação para o Amparo da Pesquisa do Estado de São Paulo)–SP, Brazil # 2007/04313-2; the National Health and Medical Research Council of Australia and the NCI (CA88363); the Cancer Research Foundations of Radiumhemmet and the Swedish Cancer Society; the Paulsson Trust, Lund University; grant support from the Swedish Cancer Society and European Research Council Advanced Grant (ERC-2011-294576); grants from Fondo de Investigaciones Sanitarias P.I. 09/01393 and P.I. 12/00840, Spain; the CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co-funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, Una manera de hacer Europa; the AGAUR 2009 SGR 1337 and AGAUR 2014_SGR_603 of the Catalan Government, Spain; Fundació La Marató de TV3, 201331-30, Catalonia, Spain; the Italian Association for Cancer research (AIRC) n. 15460 to PG, Italian Ministry of Health (5 × 1000 funds to IRCCS San Martino-IST, Genoa); the Programme Hospitalier de Recherche Clinique (PHRC-AOM-07-195); grant support from Institut National du Cancer (INCA) was attributed to B B-deP. for coordination of Melanoma Oncogenetics in France; the Comisión Honoraria de Lucha Contra el Cáncer, Montevideo, Uruguay; the work of NAG was supported in part by the Dutch Cancer Society (UL 2012-5489); FC is supported by a scholarship awarded by CONACYT, Mexico (152256/158706); and AC is the recipient of Career Development Fellowships from the NHMRC (1063593) and Cancer Institute NSW (15/CDF/1-14).
Funding Information:
The University of Utah (Salt Lake City): Acknowledgment of the use of the Genetic Counseling Shared Resource supported by National Institutes of Health grant P30CA042014 awarded to the Hunstman Cancer Institute.
Publisher Copyright:
© 2017 The Authors
PY - 2017/12
Y1 - 2017/12
N2 - Germline mutations in CDKN2A are frequently identified among melanoma kindreds and are associated with increased atypical nevus counts. However, a clear relationship between pathogenic CDKN2A mutation carriage and other nevus phenotypes including counts of common acquired nevi has not yet been established. Using data from GenoMEL, we investigated the relationships between CDKN2A mutation carriage and 2-mm, 5-mm, and atypical nevus counts among blood-related members of melanoma families. Compared with individuals without a pathogenic mutation, those who carried one had an overall higher prevalence of atypical (odds ratio = 1.64; 95% confidence interval = 1.18–2.28) nevi but not 2-mm nevi (odds ratio = 1.06; 95% confidence interval = 0.92–1.21) or 5-mm nevi (odds ratio = 1.26; 95% confidence interval = 0.94–1.70). Stratification by case status showed more pronounced positive associations among non-case family members, who were nearly three times (odds ratio = 2.91; 95% confidence interval = 1.75–4.82) as likely to exhibit nevus counts at or above the median in all three nevus categories simultaneously when harboring a pathogenic mutation (vs. not harboring one). Our results support the hypothesis that unidentified nevogenic genes are co-inherited with CDKN2A and may influence carcinogenesis.
AB - Germline mutations in CDKN2A are frequently identified among melanoma kindreds and are associated with increased atypical nevus counts. However, a clear relationship between pathogenic CDKN2A mutation carriage and other nevus phenotypes including counts of common acquired nevi has not yet been established. Using data from GenoMEL, we investigated the relationships between CDKN2A mutation carriage and 2-mm, 5-mm, and atypical nevus counts among blood-related members of melanoma families. Compared with individuals without a pathogenic mutation, those who carried one had an overall higher prevalence of atypical (odds ratio = 1.64; 95% confidence interval = 1.18–2.28) nevi but not 2-mm nevi (odds ratio = 1.06; 95% confidence interval = 0.92–1.21) or 5-mm nevi (odds ratio = 1.26; 95% confidence interval = 0.94–1.70). Stratification by case status showed more pronounced positive associations among non-case family members, who were nearly three times (odds ratio = 2.91; 95% confidence interval = 1.75–4.82) as likely to exhibit nevus counts at or above the median in all three nevus categories simultaneously when harboring a pathogenic mutation (vs. not harboring one). Our results support the hypothesis that unidentified nevogenic genes are co-inherited with CDKN2A and may influence carcinogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85035010048&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2017.07.829
DO - 10.1016/j.jid.2017.07.829
M3 - Article
C2 - 28830827
AN - SCOPUS:85035010048
SN - 0022-202X
VL - 137
SP - 2606
EP - 2612
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 12
ER -